KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBIT (2016 - 2025)

Historic EBIT for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $167.6 million.

  • West Pharmaceutical Services' EBIT rose 390.58% to $167.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $587.9 million, marking a year-over-year increase of 292.37%. This contributed to the annual value of $569.9 million for FY2024, which is 1569.53% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported EBIT of $167.6 million as of Q3 2025, which was up 390.58% from $153.7 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' EBIT registered a high of $228.4 million during Q2 2022, and its lowest value of $107.0 million during Q1 2025.
  • Its 5-year average for EBIT is $166.3 million, with a median of $167.6 million in 2025.
  • Its EBIT has fluctuated over the past 5 years, first soared by 10395.75% in 2021, then tumbled by 3084.93% in 2024.
  • West Pharmaceutical Services' EBIT (Quarter) stood at $184.0 million in 2021, then dropped by 29.51% to $129.7 million in 2022, then rose by 24.06% to $160.9 million in 2023, then decreased by 0.81% to $159.6 million in 2024, then rose by 5.01% to $167.6 million in 2025.
  • Its last three reported values are $167.6 million in Q3 2025, $153.7 million for Q2 2025, and $107.0 million during Q1 2025.